0.32 USD
-0.11 (-25.06%)
0.3251 USD
+0.01 (+1.59%)
Overall VXRT gets a fundamental rating of 2 out of 10. We evaluated VXRT against 530 industry peers in the Biotechnology industry. Both the profitability and financial health of VXRT have multiple concerns. VXRT is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
VXRT had negative earnings in the past year.
In the past year VXRT has reported a negative cash flow from operations.
In the past 5 years VXRT always reported negative net income.
VXRT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -36.66%, VXRT is in line with its industry, outperforming 59.32% of the companies in the same industry.
Looking at the Return On Equity, with a value of -127.41%, VXRT is in line with its industry, outperforming 41.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.66% | ||
| ROE | -127.41% | ||
| ROIC | N/A |
ROA(3y)-66.71%
ROA(5y)-50.62%
ROE(3y)-117.91%
ROE(5y)-83.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VXRT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VXRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
VXRT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VXRT has more shares outstanding
The debt/assets ratio for VXRT has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -5.12, we must say that VXRT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.12, VXRT is doing worse than 60.04% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that VXRT is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.01, VXRT perfoms like the industry average, outperforming 42.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.12 |
ROIC/WACCN/A
WACC9.59%
2.3 Liquidity
A Current Ratio of 0.64 indicates that VXRT may have some problems paying its short term obligations.
VXRT's Current ratio of 0.64 is on the low side compared to the rest of the industry. VXRT is outperformed by 91.22% of its industry peers.
A Quick Ratio of 0.64 indicates that VXRT may have some problems paying its short term obligations.
VXRT's Quick ratio of 0.64 is on the low side compared to the rest of the industry. VXRT is outperformed by 90.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.64 | ||
| Quick Ratio | 0.64 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 49.06% over the past year.
Looking at the last year, VXRT shows a very strong growth in Revenue. The Revenue has grown by 433.37%.
Measured over the past years, VXRT shows a very strong growth in Revenue. The Revenue has been growing by 23.72% on average per year.
EPS 1Y (TTM)49.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)433.37%
Revenue growth 3Y217.11%
Revenue growth 5Y23.72%
Sales Q2Q%857.18%
3.2 Future
Based on estimates for the next years, VXRT will show a small growth in Earnings Per Share. The EPS will grow by 0.50% on average per year.
The Revenue is expected to grow by 30.95% on average over the next years. This is a very strong growth
EPS Next Y15.8%
EPS Next 2Y-6.58%
EPS Next 3Y-9.17%
EPS Next 5Y0.5%
Revenue Next Year-37.03%
Revenue Next 2Y-48.87%
Revenue Next 3Y-34.32%
Revenue Next 5Y30.95%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VXRT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VXRT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as VXRT's earnings are expected to decrease with -9.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.58%
EPS Next 3Y-9.17%
5. Dividend
5.1 Amount
VXRT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.32
-0.11 (-25.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners12.07%
Inst Owner Change-89.66%
Ins Owners1.03%
Ins Owner Change3.57%
Market Cap73.03M
Revenue(TTM)47.40M
Net Income(TTM)-58.12M
Analysts86.67
Price Target3.06 (856.25%)
Short Float %1.77%
Short Ratio0.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.06%
Min EPS beat(2)31.15%
Max EPS beat(2)50.98%
EPS beat(4)3
Avg EPS beat(4)-26.88%
Min EPS beat(4)-230.84%
Max EPS beat(4)50.98%
EPS beat(8)7
Avg EPS beat(8)-4.36%
EPS beat(12)10
Avg EPS beat(12)-1.05%
EPS beat(16)13
Avg EPS beat(16)-0.9%
Revenue beat(2)1
Avg Revenue beat(2)43%
Min Revenue beat(2)-28.31%
Max Revenue beat(2)114.31%
Revenue beat(4)3
Avg Revenue beat(4)1682.62%
Min Revenue beat(4)-28.31%
Max Revenue beat(4)6175.49%
Revenue beat(8)7
Avg Revenue beat(8)1313.72%
Revenue beat(12)7
Avg Revenue beat(12)849.62%
Revenue beat(16)7
Avg Revenue beat(16)625.02%
PT rev (1m)-35.71%
PT rev (3m)-35.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.83%
EPS NY rev (1m)0%
EPS NY rev (3m)9.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-82.09%
Revenue NY rev (1m)38.91%
Revenue NY rev (3m)323.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.54 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.6 | ||
| P/tB | 1.94 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.21
BVpS0.2
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.66% | ||
| ROE | -127.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-66.71%
ROA(5y)-50.62%
ROE(3y)-117.91%
ROE(5y)-83.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 6.2% | ||
| Cap/Sales | 1.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.64 | ||
| Quick Ratio | 0.64 | ||
| Altman-Z | -5.12 |
F-Score5
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)64.4%
Cap/Depr(5y)72.15%
Cap/Sales(3y)3209.1%
Cap/Sales(5y)2046.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y15.8%
EPS Next 2Y-6.58%
EPS Next 3Y-9.17%
EPS Next 5Y0.5%
Revenue 1Y (TTM)433.37%
Revenue growth 3Y217.11%
Revenue growth 5Y23.72%
Sales Q2Q%857.18%
Revenue Next Year-37.03%
Revenue Next 2Y-48.87%
Revenue Next 3Y-34.32%
Revenue Next 5Y30.95%
EBIT growth 1Y30.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.76%
OCF growth 3YN/A
OCF growth 5YN/A
VAXART INC / VXRT FAQ
Can you provide the ChartMill fundamental rating for VAXART INC?
ChartMill assigns a fundamental rating of 2 / 10 to VXRT.
What is the valuation status for VXRT stock?
ChartMill assigns a valuation rating of 0 / 10 to VAXART INC (VXRT). This can be considered as Overvalued.
What is the profitability of VXRT stock?
VAXART INC (VXRT) has a profitability rating of 1 / 10.
How financially healthy is VAXART INC?
The financial health rating of VAXART INC (VXRT) is 1 / 10.
Can you provide the expected EPS growth for VXRT stock?
The Earnings per Share (EPS) of VAXART INC (VXRT) is expected to grow by 15.8% in the next year.